|
|
|
| Estabilishment and Application of a Model for Drug Screening Targeting Neprilysin Proteinase |
| TIAN Cong-hui1,2, TANG Yan-ting2,3, WANG Quan2,3, ZHOU Hong-gang4 |
1. College of Biological Engineering, Tianjin University of Science & Technology, Tianjing 300457, China;
2. Tianjin International Joint Academy of Biotechnology & Medicne, Tianjin 300457, China;
3. MDCbiotechnology Co.Ltd, Tianjin 300457, China;
4. College of Pharmacy, Nankai University, Tianjin 300457, China |
|
|
|
Abstract Objective: To establish a viable high-throughput drug screening model targeting on NEP proteinase, and applied the model to screen inhibitors. Methods: Target protein was obtained using Pichia expression system. The gene of NEP was amplified with PCR and cloned into the expression vector pPICZα-A, and using the X-33 Pichia strain as the host for expression of recombinant proteins. Then, proteinase activity of target protein was examined by fluorescence resonance energy transfer(FRET)assays. Finally, a model for drug screening was established and optimized before abundant inhibitors screening. Results: It was not only successfully constructed the expression vector pPICZα-A-NEP, but also established a model for drug screening targeting NEP. Several related kinetic parameters were also obtained.The determination of Z-factor in model was 0.89, indicating that a reliable and stable model for drug screening was established. Furthermore, natural component library was screened, and four inhibitors with high inhibition ratio was finally obtained when the drug concentration was less than 0.5mg/ml. Moreover,the IC50 of MDCNCL01000242 is minimal, namely 8.31 μg/ml. Conclusion: The established model targeting NEP proteinase is suitable for inhibitors screening, which can be used to promote research and development of drug.
|
|
Received: 09 October 2014
Published: 25 February 2015
|
|
|
|
|
|
[1] Roger V L, Go A S, Lloyd-Jones D M, et al. Executive summary: Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation,2012, 125:188-197.
[2] Heidenreich PA, Albert N M, Allen L A, et al. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circ Heart Fail, 2013,6: 606-619.
[3] Jørgensen T, Capewell S, Prescott E, et al. Population-level changes to promote cardiovascular health
[J].VnitrLek, 2012,58(12):943-954.
[4] Knecht M, Pangl I, Langenickel T, et al. Increased ex Pression of renal neutral endopeptidase in severe heart failure. Life Sci, 2002,71 (23): 2701 - 2712.
[5] Kerr M A, Kenny A J. The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J,1974,137:477-488.
[6] Olins G M, Spear K L, Siegel N R, et al.Atrial peptide inactivation by rabbit-kidney brush-border membranes.Eur J Biochem,1987,170(1-2):431-434.
[7] Campbell D J, Anastasopoulos F, Duncan A M. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. Pharmacology and Experimental Therapeutics,1998,287(2):567-577.
[8] Cao Z, Burrell L M, Tikkanen I, et al. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomised rats. Kidney Int,2001,60:715-721.
[9] Taal M W, Nenov V D, Wong W, et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol, 2001,12:2051-2059.
[10] Palaniyappan A, Uwiera R R E, Idikio H, et al. Comparison of vasopeptidase inhibitor omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction. Molecular and Cellular Biochemistry, 2009, 321(1-2): 9-22.
[11] Neal B, MacMahon S, Ohkubo T, et al. Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease. J Renin Angiotensin Aldosterone Syst, 2002, 3:270-276.
[12] Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol, 2010, 50:401-414.
[13] Solomon S D, Zile M, Pieske B.The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.The Lancet, 2012,380(9851):1387-1395.
[14] Vardeny O, Tacheny T, Solomon S D. First-in-class angiotensin receptor neprilysin inhibitor in heart failure.Clin Pharmacol Ther, 2013,94(4):445-448.
[15] McMurray J J,Packer M, Desai A S, et al. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).Eur J Heart Fail, 2014,16(7):817-825.
[16] Zhang L,Shang N Y,Du G H.Establishment and application of high throughput screening for discovery of new antidepressants.Chin Pharm J,2003,38(4):263- 266.
[17] 苏华, 何飞. 高通量筛选技术在天然药物研究中的应用进展. 中华中医药学刊,2013, 31(1): 144-146. Su H, He F. Advances on the high-throughput screening of natural drugs.Chinese Archives of Traditional Chinese Medicine,2013,31(1):144-146.
[18] 中国科学院昆明植物研究所.云南植物志,第8卷.北京:科学出版社,1997.210-211. Kunming Institute of Botany.Flora of Yunnan.vol(8).Beijing:Science Press,1997.210-211.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
